Literature DB >> 14764033

Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor beta and vascular endothelial growth factor.

M Sönmezer1, M Güngör, A Ensari, F Ortaç.   

Abstract

We aimed to evaluate the prognostic significance of microvessel density (MVD), vascular endothelial growth factor (VEGF), and transforming growth factor beta (TGFbeta), as well as to find out the relationship between MVD, and VEGF and TGFbeta in epithelial ovarian cancer (EOC). Surgical specimens of 47 patients with stage I-IV primary EOC, who underwent extended surgical staging according to FIGO, were investigated. Five- micro m thick tissue sections were immunostained with antibody to factor VIII-related antigen, and MVD was assessed at three separate areas of x200 magnification. Expressions for VEGF and TGFbeta were evaluated by immunohistochemical staining using related monoclonal antibodies. Results were correlated with clinicopathologic factors and survival. We did not find any correlation between MVD and clinicopathologic factors, or patient survival. Similarly, there was no association between the degree of VEGF staining and survival or clinicopathologic factors, except preoperative ascites volume, which was higher in patients showing moderate and intense VEGF staining than those with weak VEGF staining (P = 0.052). The expression of TGFbeta was inversely correlated with preoperative CA-125 levels (P < 0.05). Furthermore, there was no correlation between MVD and the staining intensity of VEGF or TGFbeta. In conclusion, angiogenesis does not appear as a prognostic factor in EOC. We suggest that VEGF is an important mediator of ascites formation, and that TGFbeta, which is supposed to have tissue-specific actions in tumorigenesis, may have growth-inhibitory functions in EOC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764033     DOI: 10.1111/j.1048-891x.2004.14202.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  8 in total

1.  Clinical significance of serum transforming growth factor-beta 1 (TGF-β1) levels in patients with epithelial ovarian cancer.

Authors:  Faruk Tas; Senem Karabulut; Murat Serilmez; Rumeysa Ciftci; Derya Duranyildiz
Journal:  Tumour Biol       Date:  2013-12-06

2.  Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application.

Authors:  Afshin Amini; Samar Masoumi Moghaddam; David L Morris; Mohammad H Pourgholami
Journal:  J Oncol       Date:  2011-09-26       Impact factor: 4.375

3.  Antitumor effect of sFlt-1 gene therapy system mediated by Bifidobacterium Infantis on Lewis lung cancer in mice.

Authors:  H Zhu; Z Li; S Mao; B Ma; S Zhou; L Deng; T Liu; D Cui; Y Zhao; J He; C Yi; Y Huang
Journal:  Cancer Gene Ther       Date:  2011-09-16       Impact factor: 5.987

4.  Role of lymphangiogenesis in epithelial ovarian cancer.

Authors:  S S Sundar; H Zhang; P Brown; S Manek; C Han; K Kaur; M F L Charnock; D Jackson; T S Ganesan
Journal:  Br J Cancer       Date:  2006-06-05       Impact factor: 7.640

5.  Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) in Patients With Serous Ovarian Carcinoma and Their Clinical Significance.

Authors:  Reza Ranjbar; Foroogh Nejatollahi; Ahmad Sina Nedaei Ahmadi; Hossein Hafezi; Akbar Safaie
Journal:  Iran J Cancer Prev       Date:  2015-08-24

Review 6.  Mechanisms of Vasculogenic Mimicry in Ovarian Cancer.

Authors:  Lízbeth Ayala-Domínguez; Leslie Olmedo-Nieva; J Omar Muñoz-Bello; Adriana Contreras-Paredes; Joaquín Manzo-Merino; Imelda Martínez-Ramírez; Marcela Lizano
Journal:  Front Oncol       Date:  2019-09-27       Impact factor: 6.244

Review 7.  Antiangiogenic drugs in ovarian cancer.

Authors:  G C Kumaran; G C Jayson; A R Clamp
Journal:  Br J Cancer       Date:  2008-11-11       Impact factor: 7.640

8.  A current review of targeted therapeutics for ovarian cancer.

Authors:  Susana M Campos; Sue Ghosh
Journal:  J Oncol       Date:  2010-01-03       Impact factor: 4.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.